Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine versus remifentanil for treatment-resistant major depressive disorder
ACTRN12615000573550Phase 3Completed
- Sponsor
- The University of Auckland
- Start
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of ketamine in major depressive disorder (MDD) (2 arms), sponsored by The University of Auckland. Primary endpoint: Montgomery-Asberg Depression Rating Scale (MADRS). Started Oct 2016; status: completed.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ACTRN12615000573550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12615000573550.